2019-04-08 - OBSERVABLE Face-to-face Meeting

2019-04-08 - OBSERVABLE Face-to-face Meeting

 

Date and time

2019-04-08 13.30 UTC

Attendees

In the room: @Brian Carlsen @Former user (Deleted) @Rob Hausam @r.dash @Former user (Deleted) @gansel (Deactivated) @Former user (Deleted) @Scott Campbell @Former user (Deleted) @Jeff Wilcke @Farzaneh Ashrafi @Ed Cheetham @Zac.Whitewood-Moores @Jim Campbell @Jostein Ven @Laszlo Igali @Mikko Härkönen Dr. Ramamurthi Vanakara Venicata, IN

Online: @Piper Ranallo PhD@Suzanne Santamaria

Apologies

 

Objectives

  • Decide on susceptibility modelling

  • Introduce cognitive function observables

  • Invite Mental and Behavioral Health CRG

  • Discuss international lab interoperability

Discussion items

 

Item

Description

Owner

Notes

Action

 

Item

Description

Owner

Notes

Action

 

1

Welcome & apologies

@Daniel Karlsson

  • Remember recording!

 

 

2

Conflicts of interest

@Daniel Karlsson

  • None stated

 

 

3

Susceptibility observables

@Daniel Karlsson @Farzaneh Ashrafi @Suzanne Santamaria

Background

Draft editorial guidelines: Editorial Guidelines for Diagnostic Products Used for Susceptibility Testing

It was decided to recommend representation the physical form of the susceptibility test product, and also to use the | has presentation strenght... | attributes (as opposed to other strength attributes).

Two issues were discovered while re-reading the Inception/Elaboration document for susceptibility testing: 1. "oral form antibiotic susceptibility" exists as components in LOINC tests. 2. when other methods than culture are used, e.g. PCR or sequencing, to determine susceptibility, we might need to use another way of modeling, e.g. beta-lactamase producing ~ resistance towards beta-lactam antibiotics.

While the Susceptibility test products are needed for the mycobacteria tests (with strength-specified antibiotics), we might reconsider the approach for other cases, and use substances where products are not needed, together with a role chain | towards | o | ingredient | → | towards |.

Rob: Aren't all susceptibility tests strength-specified, even though the strength is not part of the definition?

Xavier: EUCAST breakpoint for diffusion disks : http://www.eucast.org/clinical_breakpoints/ the xls is at http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Preliminary_v_9.0_Breakpoint_Tables_for_consultation.xlsxbreakpoint requires a definite antibio amount in the disk.

Most tests (mycobacteria tests being an exception) are based on there being a concentration gradient (e.g. disk diffusion, etest, MIC procedures) and thus not a single concentration.

2019-02-11:

An OWL ontology with Diagnostic test products and susceptibility observables is attached.

The combination substances are to be inactivated, so modeling cannot rely on use of such concepts.

2019-03-25:

An alternative version not using combination substances was presented and discussed.

Current objective

Presentation

Give recommendations on representation given two alternatives: (1) use | Susceptibility test product | as values of the | towards | attribute OR (2) use Substance together with | direct substance | = | Susceptibility test product | only when needed.

2019-04-08:

Presentation of alternatives for susceptibility observables modelling.

Has use with information models, e.g. FHIR Observation, been tested? No, but given that the observables are expression representations of LOINC content, for which there is ample experience, that is assumed not to be a problem.

Can Susceptibility test products be categorized as Pharmaceutical products, and thus be placed under 373873005 | Pharmaceutical / biologic product (product) |?

Comparison with allergy tests (skin or blood) can be explored further.

The project group voted to have a full example of using Test products as values for towards presented at next meeting (Motion: @Jim Campbell , second: @r.dash. Against: 0, Abstain: 1, For 5). @Former user (Deleted) to be invited to discuss placement of Susceptibility test products.

@Daniel Karlsson will produce a new version of the ontology according to the "towards test product" and present at next meeting, including retrieval use cases.

 

4

@Jim Campbell

(Cognitive) Function observables

See this page.

2019-04-08:

Presentation of work done by @Jim Campbell et al. at UNMC. Observables had been developed for MMSE (Mini-mental state examination). Process, scale type, and property concepts had been created in order to define the MMSE observables. Also, the section about function observables in the Observables I/E document was expanded.

The level of detail of Observables for individual instrument parts, such as the individual questions of MMSE, was discussed. Alternatively, generic observables, not specific to the instrument, could be used. UNMC preferred having specific observables.

The function observables are, according to the current pattern, defined by reference to the processes which are realized by the function, e.g. Orientation in time is realized by the function Ability to orient in time. Other observables can be defined by reference to the processes, e.g. performance of processes. Alternatively, these observables could be defined in terms of the function rather than the process.

 

 

5

@Jim Campbell

@Daniel Karlsson

Lab observables interoperability

See this page.

2019-04-08:

@Jim Campbell presented a request to SNOMED International to publish an OWL ontology including the LOINC expressions and expressions for any other lab terminology (e.g. NPU Terminology or the NHS pathology subset and content in SNOMED to allow classification, and comparison, of lab content.

The group was supportive of the proposal.

 

 

6

Next meeting

@Daniel Karlsson

  • Next meeting will be 2019-05-20

 

 

7

AOB

@Daniel Karlsson

Bullet points for the closing plenary presentation:

  • Almost concluded susceptibility observables

  • Cognitive function observables, joint with MBH CRG, next steps identified

  • Agreement of use of Observables model for international lab interoperability

 

 

Meeting Files

  File Modified
No files shared here yet.

Recordings

https://snomed.zoom.us/recording/share/f0mOp-HwKOxr42rmPLdRqDKxqbyElbNs_ARB7jCXNmewIumekTziMw 

More Zoom details

Topic: Observables meeting

Time: this is a recurring meeting Meet anytime

Join from PC, Mac, Linux, iOS or Android:
https://snomed.zoom.us/j/992630241

Or Telephone:
Dial:
+46 (0) 8 4468 2488 (SE Toll)
+61 (0) 2 8015 2088 (AU Toll)
+32 (0) 2 588 4188 (BE Toll)
+1 647 558 0588 (CA Toll)
+56 41 256 0288 (CL Toll)
+420 2 2888 2388 (CZ Toll)
+45 89 88 37 88 (DK Toll)
+372 880 1188 (EE Toll)
+852 5808 6088 (HK Toll)
+353 (0) 1 691 7488 (IE Toll)
+972 (0) 3 978 6688 (IL Toll)
+370 5214 1488 (LT Toll)
+60 3 9212 1727 (MY Toll)
+356 2778 1288 (MT Toll)
+31 (0) 20 241 0288 (NL Toll)
+64 (0) 9 801 1188 (NZ Toll)
+64 (0) 4 831 8959 (NZ Toll)
+47 2396 0588 (NO Toll)
+48 22 307 3488 (PL Toll)
+351 308 804 188 (PT Toll)
+65 3158 7288 (SG Toll)
+421 233 056 888 (SK Toll)
+386 1888 8788 (SI Toll)
+34 91 198 0188 (ES Toll)
+41 (0) 31 528 0988 (CH Toll)
+44 (0) 20 3695 0088 (GB Toll)
+1 408 638 0968 (US Toll)
+1 646 876 9923 (US Toll)
+1 669 900 6833 (US Toll)

Meeting ID: 992 630 241

International numbers available: https://snomed.zoom.us/zoomconference?m=AQWV2VqAIGYWMcMapl9CoYjsaj1TVS7K

 

Copyright © 2025, SNOMED International